Microinjections of the dopamine D2 receptor antagonist sulpiride into the medial prefrontal cortex attenuate glucocorticoid-induced impairment of long-term memory retrieval in rats

Pakdel, Roghayeh; Rashidy-Pour, Ali

doi:10.1016/j.nlm.2006.10.002

Cited by 22 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the role of frontocortical dopaminergic mechanisms in cognitive function (Robbins, 2002;Tanaka, 2006;El-Ghundi et al, 2007), microinjection of S33138 into the FCX improved social recognition. Although effects of frontocortical administration of mixed D 2 /D 3 antagonists have proven variable in other models, this finding suggests that instances of procognitive actions reflect blockade of D 3 rather than D 2 receptors (Passetti et al, 2001;Chudasama and Robbins, 2004;Pakdel and Rashidy-Pour, 2007). The present observations also accord with evidence that a dysfunction of the FCX contributes to disturbed social cognition in schizophrenia (Lee et al, 2006).…”

Section: Elevation By S33138 Of Extracellular Levels Of Histamine Butsupporting

confidence: 80%

S33138 (N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects

Millan¹,

Loiseau²,

Dekeyne³

et al. 2008

The Journal of Pharmacology and Experimental Therapeutics

View full text Add to dashboard Cite

In contrast to clinically available antipsychotics, the novel benzopyranopyrrolidine derivative, S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]benzopyrano [3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), behaves as a preferential antagonist of D 3 versus D 2 receptors and does not interact with histamine H 1 and muscarinic receptors. In contrast to haloperidol, clozapine, olanzapine, and risperidone, S33138 (0.16 -2.5 mg/kg s.c.) did not disrupt performance in passive-avoidance and five-choice serial reaction time procedures. Furthermore, upon either systemic administration (0.04 -2.5 mg/kg s.c.) or introduction into the frontal cortex (0.04 -0.63 g/side), S33138 potently attenuated the perturbation of social recognition by scopolamine or a prolonged intersession delay. Over a comparable and low-dose range, S33138 (0.04 -0.63 mg/kg s.c.) elevated dialysis levels of acetylcholine in the frontal cortex of freely moving rats. At higher doses (2.5-10.0 mg/kg s.c.), S33138 also increased frontocortical levels of histamine, whereas monoamines, glutamate, glycine, and GABA were unaffected. By analogy to the other antipsychotics, S33138 (0.63-10.0 mg/kg s.c.) inhibited conditioned avoidance responses in rats, apomorphine-induced climbing in mice, and hyperlocomotion elicited by amphetamine, cocaine, dizocilpine, ketamine, and phencyclidine in rats. S33138 (0.16 -2.5 mg/kg s.c.) also blocked the reduction of prepulse inhibition elicited by apomorphine. In comparison with the above actions, only "high" doses of S33138 (10.0 -40.0 mg/kg s.c.) elicited catalepsy. To summarize, reflecting preferential blockade of D 3 versus D 2 receptors, S33138 preserves and/or enhances cognitive function, increases frontocortical cholinergic transmission, and is active in models of antipsychotic properties at doses well below those inducing catalepsy. In comparison with clinically available agents, S33138 displays, thus, a distinctive and promising profile of potential antipsychotic properties.We have recently described a novel benzopyranopyrrolidine derivative, S33138 (Millan et al., 2008a,b) that behaves as a preferential antagonist at cloned, human, and native cerebral dopaminergic D 3 versus D 2 receptors. In addition, it displays modest antagonist properties at serotonin (5-HT) 2A receptors, 5-HT 7 receptors, and ␣ 2C -adrenoceptors (ARs), blockade of which may also be useful in the treatment of schizophrenia Svensson, 2003). In contrast, S33138 does not interact with histamine H 1 , muscarinic, or ␣ 1 -adrenoceptors, antagonism of which provokes cardiovascular-autonomic side effects (Kroeze et al., 2003;Lieberman, 2005). This distinctive receptor-binding profile differentiates S33138 from clinically employed antipsychotics like the neuroleptic and D 2 /D 3 receptor antagonist, haloperidol; the "atypical" agent, clozapine; and two further mulArticle, publication date, and citation information can be found at

show abstract

Section: Elevation By S33138 Of Extracellular Levels Of Histamine Butsupporting

confidence: 80%

S33138 (N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects

Millan¹,

Loiseau²,

Dekeyne³

et al. 2008

The Journal of Pharmacology and Experimental Therapeutics

View full text Add to dashboard Cite

show abstract

“…Furthermore, other forms of memory such as inhibitory avoidance and conditioned fear extinction have also been linked to D 2 receptor deactivation in other brain areas (Pakdel & Rashidy-Pour, 2007;Ponnusamy, Nissim, & Barad, 2005).…”

Section: Discussionmentioning

confidence: 99%

The roles of accumbal dopamine D1 and D2 receptors in maternal memory in rats.

Parada¹,

King²,

Li³

et al. 2008

Behavioral Neuroscience

View full text Add to dashboard Cite

Female rats show enhanced maternal responsiveness toward their young if they have had maternal experiences before. This kind of maternal experience-based memory is critically dependent on the mesolimbic dopamine (DA) system, especially the nucleus accumbens (NA) shell. However, the relative contributions of the two main DA receptor systems (D 1 and D 2 ) within the shell have not been delineated. This study investigates the roles of dopamine D 1 and D 2 receptors in maternal memory by infusing a selective D 1 antagonist, SCH-23390; a selective D 2 antagonist, sulpiride; or a combination D 1 /D 2 antagonist, cis-Z-flupenthixol, into the NA shell of postpartum female rats. Sulpiride-infused rats showed a significantly longer latency to exhibit full maternal behavior following a 10-day pup isolation period in comparison to the controls that received a vehicle. Cis-Z-flupenthixol disrupted maternal memory to a greater extent, as rats receiving this showed the longest latencies to express maternal behavior. SCH-23390 infusions had only marginal effects. These findings suggest that both the D 1 and the D 2 receptor subtypes play a role in the consolidation of maternal memory and they might do so by mediating the motivational salience of pup stimulation.

show abstract

“…While promoting new learning, acute corticosterone increases may impair reconsolidation of existing memories (Cai, Blundell, Han, Greene, & Powell, 2006; Pakdel & Rashidy-Pour, 2007) providing an additional mechanism for the creation of adaptive memories for clinical interventions.…”

Section: Cortisol For the Augmentation Of Extinction Consolidationmentioning

confidence: 99%

Cognitive enhancers for anxiety disorders

Hofmann

Smits

Asnaani

et al. 2011

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

Cognitive behavioral therapy is an effective intervention for anxiety disorders. However, a significant number of people do not respond or only show partial response even after an adequate course of the treatment. Recent research has shown that the efficacy of the intervention can be improved by the use of cognitive enhancers that augment the core learning processes of cognitive-behavior therapy. This manuscript provides a review of the current state of cognitive enhancers for the treatment of anxiety disorders.

show abstract

Microinjections of the dopamine D2 receptor antagonist sulpiride into the medial prefrontal cortex attenuate glucocorticoid-induced impairment of long-term memory retrieval in rats

Cited by 22 publications

References 25 publications

S33138 (N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects

S33138 (N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects

The roles of accumbal dopamine D1 and D2 receptors in maternal memory in rats.

Cognitive enhancers for anxiety disorders

Contact Info

Product

Resources

About